Evidence map›Paper›PMID 38017122›Full record

ArticleAnnals of surgical oncology2024

Association of Race, Ethnicity, Language, and Insurance with Time to Treatment Initiation Among Women with Breast Cancer at an Urban, Academic, Safety-Net Hospital.

Brendin R Beaulieu-Jones, Emily J Ha, Ann Fefferman, Judy Wang, Sophie H Chung, Jennifer F Tseng, Andrea Merrill, Teviah E Sachs, Naomi Y Ko, Michael R Cassidy

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Brendin R Beaulieu-JonesDepartment of Surgery, Boston Medical Center, Boston, MA, USA.
Emily J HaBoston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Ann FeffermanBoston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Judy WangBoston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Sophie H ChungDepartment of Surgery, Boston Medical Center, Boston, MA, USA.
Jennifer F TsengBoston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Andrea MerrillBoston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Teviah E SachsBoston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Naomi Y KoBoston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Michael R CassidyBoston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. Michael.Cassidy@bmc.org.ORCID http://orcid.org/0000-0002-0522-8667
Boston University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInitial treatment for nonmetastatic breast cancer is resection or neoadjuvant systemic therapy, depending on tumor biology and patient factors. Delays in treatment have been shown to impact survival and quality of life. Little has been published on the performance of safety-net hospitals in delivering timely care for all patients.

methodsWe conducted a retrospective study of patients with invasive ductal or lobular breast cancer, diagnosed and treated between 2009 and 2019 at an academic, safety-net hospital. Time to treatment initiation was calculated for all patients. Consistent with a recently published Committee on Cancer timeliness metric, a treatment delay was defined as time from tissue diagnosis to treatment of greater than 60 days.

resultsA total of 799 eligible women with stage 1-3 breast cancer met study criteria. Median age was 60 years, 55.7% were non-white, 35.5% were non-English-speaking, 18.9% were Hispanic, and 49.4% were Medicaid/uninsured. Median time to treatment was 41 days (IQR 27-56 days), while 81.1% of patients initiated treatment within 60 days. The frequency of treatment delays did not vary by race, ethnicity, insurance, or language. Diagnosis year was inversely associated with the occurrence of a treatment delay (OR: 0.944, 95% CI 0.893-0.997, p value: 0.039).

conclusionAt our institution, race, ethnicity, insurance, and language were not associated with treatment delay. Additional research is needed to determine how our safety-net hospital delivered timely care to all patients with breast cancer, as reducing delays in care may be one mechanism by which health systems can mitigate disparities in the treatment of breast cancer.

Indexed as

Breast NeoplasmsEthnicityFemaleHealthcare DisparitiesHumansInsurance CoverageLanguageMiddle AgedQuality of LifeRetrospective StudiesSafety-net ProvidersTime-to-TreatmentUnited StatesBreast cancerHealth disparitiesOncologySafety-net hospitalTreatment delays

Identifiers

PMID38017122
OpenAlexW4389079680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.